Literature DB >> 9443404

Cross-resistance to methotrexate and metals in human cisplatin-resistant cell lines results from a pleiotropic defect in accumulation of these compounds associated with reduced plasma membrane binding proteins.

D Shen1, I Pastan, M M Gottesman.   

Abstract

Cross-resistance to a wide array of toxic chemicals is a common phenomenon in cisplatin-resistant cell lines. In this study, two independently isolated cisplatin-resistant cell lines derived from a human hepatoma and a cervical adenocarcinoma were shown to be cross-resistant to methotrexate (MTX) and several metal salts, such as sodium arsenite, sodium arsenate, antimony potassium tartrate, and cadmium chloride. A pleiotropic defect resulting in reduced accumulation of cisplatin, 3[H]MTX, 73As3+, and 73As5+ was found in both cisplatin-resistant cell lines. Analysis by immunoblot, indirect immunofluorescence, and Northern hybridization showed dramatically reduced expression of the folate binding protein that mediates MTX uptake in both human cisplatin-resistant cell lines. By photoaffinity labeling with UV irradiation, specific binding proteins of Mr 230,000 and Mr 48,000 for 73As3+ and Mr 190,000 for 73As5+ were found in enriched plasma membrane of both human cisplatin-sensitive parental cell lines. Expression of these specific binding proteins was decreased in cells selected for cisplatin resistance. A protein band at Mr 36,000 that binds to 73As3+ was overexpressed in both human cisplatin-resistant cell lines. The finding of loss of distinct binding proteins for MTX, arsenate, and arsenite in association with decreased accumulation of these agents in cisplatin-resistant cells suggests a pleiotropic, possibly regulatory, alteration in these cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9443404

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  26 in total

1.  Elevated expression of TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance.

Authors:  Ding-Wu Shen; Jichun Ma; Mitsunori Okabe; Guofeng Zhang; Di Xia; Michael M Gottesman
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

2.  Mitaplatin increases sensitivity of tumor cells to cisplatin by inducing mitochondrial dysfunction.

Authors:  Xue Xue; Song You; Qiang Zhang; Yan Wu; Guo-Zhang Zou; Paul C Wang; Yu-Liang Zhao; Yan Xu; Lee Jia; Xiaoning Zhang; Xing-Jie Liang
Journal:  Mol Pharm       Date:  2012-02-13       Impact factor: 4.939

3.  Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.

Authors:  Jean-Pierre Gillet; Anna Maria Calcagno; Sudhir Varma; Miguel Marino; Lisa J Green; Meena I Vora; Chirayu Patel; Josiah N Orina; Tatiana A Eliseeva; Vineet Singal; Raji Padmanabhan; Ben Davidson; Ram Ganapathi; Anil K Sood; Bo R Rueda; Suresh V Ambudkar; Michael M Gottesman
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-08       Impact factor: 11.205

Review 4.  Delivery of intracellular-acting biologics in pro-apoptotic therapies.

Authors:  Hongmei Li; Chris E Nelson; Brian C Evans; Craig L Duvall
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

Review 5.  A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments.

Authors:  Kenta Masui; Beatrice Gini; Jill Wykosky; Ciro Zanca; Paul S Mischel; Frank B Furnari; Webster K Cavenee
Journal:  Carcinogenesis       Date:  2013-03-01       Impact factor: 4.944

6.  Identification and characterization of a 66-68-kDa protein as a methotrexate-binding protein in murine leukemia L1210 cells.

Authors:  Tuoen Liu; Allison Dean; Saint Ashwini; Peter P Sheridan; Alok Bhushan; James C K Lai; Shousong Cao; Christopher K Daniels
Journal:  Cell Stress Chaperones       Date:  2012-10-23       Impact factor: 3.667

7.  Say no to DMSO: dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes.

Authors:  Matthew D Hall; Katherine A Telma; Ki-Eun Chang; Tobie D Lee; James P Madigan; John R Lloyd; Ian S Goldlust; James D Hoeschele; Michael M Gottesman
Journal:  Cancer Res       Date:  2014-05-08       Impact factor: 12.701

8.  Enhancing effectiveness of the MDR-sensitive compound T138067 using advanced treatment with negative modulators of the drug-resistant protein survivin.

Authors:  Xiang Ling; Xiang He; Pasha Apontes; Felicia Cao; Rami G Azrak; Fengzhi Li
Journal:  Am J Transl Res       Date:  2009-07-15       Impact factor: 4.060

9.  Reduced endocytosis and altered lysosome function in cisplatin-resistant cell lines.

Authors:  S S Chauhan; X J Liang; A W Su; A Pai-Panandiker; D W Shen; J A Hanover; M M Gottesman
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

10.  Folate Functionalized Boron Nitride Nanotubes and their Selective Uptake by Glioblastoma Multiforme Cells: Implications for their Use as Boron Carriers in Clinical Boron Neutron Capture Therapy.

Authors:  Gianni Ciofani; Vittoria Raffa; Arianna Menciassi; Alfred Cuschieri
Journal:  Nanoscale Res Lett       Date:  2008-11-25       Impact factor: 4.703

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.